Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
221-240 of 2,120 trials

Idiopathic Inflammatory Myopathy: Efgartigimod Treatment

We are studying the long-term safety and effects of a new injection for adults with active idiopathic inflammatory myopathy. This research aims to see if it can help reduce steroid use and improve health outcomes.

Active Idiopathic Inflammatory Myopathy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Wilson Disease: UX701 Gene Therapy Study

We are evaluating a new gene therapy for adults with Wilson disease to see if it safely helps manage copper levels in the body. The study will also look at how it affects the need for current medications and overall liver health.

Wilson's Disease1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHepatologyInfectious DiseasesInternal Medicine

Pulmonary Sarcoidosis: XTMAB-16 Treatment Study

We are testing a new treatment called XTMAB-16 for people with pulmonary sarcoidosis to see if it can safely reduce the need for corticosteroids. This study will help determine the best dose and assess its effectiveness.

Pulmonary Sarcoidosis3-6 monthsSafety phase (I)Efficacy phase (II)>20 visitsInvestigational MedicinesInternal MedicinePulmonology

HIV-1 Treatment: Long-Acting Cabotegravir and Rilpivirine for Older Adults

We are studying a new long-acting treatment for people aged 60 and older living with HIV-1. The goal is to see if it effectively controls the virus and how it affects overall health.

HIV-1>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesInternal Medicine

Chemotherapy-Induced Polyneuropathy: Aconite Pain Oil Study

We are studying whether Aconite Pain Oil can help prevent and reduce symptoms of chemotherapy-induced polyneuropathy in cancer patients. The goal is to improve quality of life and manage symptoms during treatment.

Chemotherapy-Induced Polyneuropathy>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesNeurologyOncology

Kidney Stones: Furosemide Injection Study

We are investigating whether a Furosemide injection after kidney stone removal improves the chances of being stone-free and reduces the risk of infections. This study involves patients undergoing flexible ureteroscopy for kidney stones.

Kidney Stones>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementUrology

Mantle-Cell Lymphoma: KTE-X19 CAR-T Cell Therapy

We are studying a new CAR-T cell therapy for patients with relapsed or refractory mantle-cell lymphoma who responded partially to ibrutinib. The trial aims to evaluate its effectiveness and safety in improving patient outcomes.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Propionic Acidemia: mRNA-3927 Treatment Study

We are investigating the safety and effectiveness of mRNA-3927 in individuals with propionic acidemia. The study aims to see if this treatment can reduce serious health events related to the condition.

Propionic AcidemiaSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesEndocrinologyInternal Medicine

HPV Vaccination Timing After Stem Cell Transplant

We are comparing early versus late vaccination with Gardasil 9® in patients who have had a stem cell transplant. The goal is to see which timing produces a stronger immune response against HPV.

Recipients of Allogeneic Stem Cell TransplantationEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious DiseasesOncology

Eptinezumab for Migraines in Children and Adolescents

We are studying the long-term safety of eptinezumab in children and teens aged 6 to 17 who experience chronic or episodic migraines. This research aims to ensure the medication is safe for young patients.

Migraine6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Fronto-Temporal Dementia: LY3884963 Treatment Study

We are testing a new injection for patients with fronto-temporal dementia due to progranulin mutations. The study aims to evaluate its safety and effects on a key protein related to the disease.

Frontotemporal Dementia>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Partial Lipodystrophy: Metreleptin Treatment Study

We are studying the daily use of metreleptin in patients with partial lipodystrophy to see if it improves their condition and related health factors. This includes looking at liver health and insulin sensitivity over time.

Partial Lipodystrophy>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Idiopathic Pulmonary Fibrosis: Axatilimab Study

We are testing a new medication, axatilimab, for people with idiopathic pulmonary fibrosis to see if it improves lung function and overall quality of life compared to a placebo.

Idiopathic Pulmonary Fibrosis6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Prostate Cancer: AAA617 Treatment Study

We are studying a new drug, AAA617, for adult men with oligometastatic prostate cancer to see if it can delay disease progression compared to standard observation. This trial aims to evaluate its effects on survival and quality of life.

Oligometastatic Prostate Cancer3-6 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Lung Cancer Treatment: DZD9008 vs. Chemotherapy

We are studying a new medication, DZD9008, for patients with advanced non-small cell lung cancer that has a specific genetic mutation. The goal is to see if it works better than standard chemotherapy.

Advanced Non-Small Cell Lung Cancer with EGFR MutationConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPulmonology

Severe Infections: MODIFY Trial

We are testing a new method to guide antibiotic treatment for severe infections, aiming to reduce unnecessary antibiotic use. This study will also evaluate how this approach impacts recovery and health outcomes.

Sepsis>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Metastatic Leiomyosarcoma: Lurbinectedin and Doxorubicin Study

We are investigating whether combining lurbinectedin with doxorubicin helps patients with metastatic leiomyosarcoma live longer without disease progression compared to doxorubicin alone. This study aims to improve treatment options for this rare cancer.

Metastatic Leiomyosarcoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Advanced Breast Cancer: Giredestrant vs. Fulvestrant

We are studying a new medication, giredestrant, to see if it works better than fulvestrant for patients with advanced breast cancer who have not responded to prior hormone therapy. The trial will also evaluate the safety of both treatments.

Estrogen Receptor Positive, HER2 Negative Advanced Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Early Breast Cancer: Ribociclib with Endocrine Therapy

We are studying the effects of ribociclib combined with endocrine therapy in patients with HR-positive, HER2-negative early breast cancer. This trial aims to understand how well this treatment works and its safety.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Flu Vaccine Study for Adults 65 and Older

We are testing a new adjuvanted flu vaccine to see if it works as well as a standard flu vaccine in preventing influenza in older adults. The study will also evaluate safety and immune response to the vaccine.

Influenza6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInfectious Diseases